The company's XeriSol and XeriJect platforms offer distinct advantages over existing formulations, such as eliminating the need for reconstitution, enabling long-term room temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous infusion. Xeris has three commercially available products for patient populations in endocrinology, neurology, and gastroenterology, including Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in adult patients with Cushing's Syndrome. Xeris is passionate about making medicines easier to use for patients and caregivers.